Aura Biosciences Reports Officer/Director Changes & Compensatory Info
Ticker: AURA · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1501796
| Field | Detail |
|---|---|
| Company | Aura Biosciences, INC. (AURA) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, compensation
TL;DR
Aura Biosciences filed an 8-K detailing officer/director changes and compensation plans as of March 31, 2025.
AI Summary
Aura Biosciences, Inc. filed an 8-K on April 2, 2025, reporting events as of March 31, 2025. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
Changes in key personnel and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially when coupled with compensatory arrangements, can indicate internal shifts that may affect the company's direction and stability.
Key Players & Entities
- Aura Biosciences, Inc. (company) — Registrant
- March 31, 2025 (date) — Date of earliest event reported
- April 2, 2025 (date) — Date of Report
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is March 31, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 80 Guest Street, Boston, Massachusetts, 02135.
What is the company's telephone number?
The company's telephone number, including area code, is 617 500-8864.
What other items are included in this filing besides personnel changes?
The filing also includes Financial Statements and Exhibits.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding Aura Biosciences, Inc. (AURA).